Abstract
The approval, in 2021, of long-acting cabotegravir plus rilpivirine as the first long-term antiretroviral therapy (ART) has engendered enthusiasm for its use among patients with adherence challenges, given its potential to address stigma and other challenges associated with daily pill intake. Several factors could prevent the implementation of long-acting cabotegravir plus rilpivirine in resource-poor settings, such as cold chain requirement; inactivity of long-acting cabotegravir plus rilpivirine against hepatitis B; and the requirement for dosing once a month or every 2 months, which conflicts with differentiated service delivery models that allow patients to attend clinics every 6 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
